GentiBio

GentiBio is a clinical-stage biotechnology company based in Cambridge, Massachusetts, in the United States. It is focused on developing engineered regulatory T-cell (Treg) therapies intended to treat Type 1 diabetes (T1D) and other autoimmune or acute inflammatory diseases. The company describes its mission as leveraging Treg biology to reset the body's immune system, aiming to replace systemic and less selective immunosuppressive therapies and their associated risks. At the center of GentiBio's work is a modular engineering platform that creates optimized Tregs tailored for a range of autoimmune and inflammatory diseases. The company states that it uniquely resolves key challenges of Treg therapeutics by engineering T-regulatory cells for specificity, stability, and survival, so that they can succeed where the body's own Tregs have failed. GentiBio is building both autologous and allogeneic platforms. Its off-the-shelf allogeneic approach uses proprietary immune-evasive engineering intended to shield allogeneic engineered Tregs from immune rejection and to enable cost-of-goods comparable with biologics. The company also emphasizes scalable manufacturing that can supply large patient populations. GentiBio's pipeline includes GNTI 122, a clinical-stage candidate being studied in recent-onset Type 1 diabetes. The company has announced plans to present clinical data on GNTI 122 at the 2026 Endocrine Society (ENDO) Annual Meeting. It has also published research in EMBO Molecular Medicine describing a technology for enabling durable persistence of allogeneic cell therapies. The company is led by an experienced team with deep expertise in cell therapy, immunology, and therapeutic development, supported by experienced CMC and clinical teams. Its leadership includes Chief Medical Officer Mark Bach, MD, PhD, and co-founder and Senior Vice President of Research and Development Operations Chandra Patel, PhD. GentiBio's board and scientific advisors include representatives from investors such as OrbiMed and the Novartis Venture Fund, as well as scientific co-founder Jane Buckner, MD, President of the Benaroya Research Institute. The company is privately held and backed by investors. It was founded on research by pioneers in the Treg, autoimmune disease, and synthetic biology fields, combining multiple technologies into an integrated Treg engineering platform.

GentiBio is a clinical-stage biotechnology company located in Cambridge, Massachusetts, United States. The company was founded on research by pioneers in the Treg, autoimmune disease, and synthetic biology fields, combining multiple technologies into a powerful, integrated Treg engineering platform. Its scientific co-founder is Jane Buckner, MD, President of the Benaroya Research Institute. GentiBio's therapeutic focus is on engineered regulatory T cells (Tregs), which it calls EngTregs. The company aims to reset the body's immune system to ameliorate autoimmune and acute inflammatory diseases. Autoimmune and inflammatory diseases affect hundreds of millions of people globally, and GentiBio believes that leveraging Treg biology can lead to cures. Its goal is to replace the need for systemic and less selective immune suppressive therapies and their associated risks. The company has built both autologous and allogeneic platforms that it describes as robust, highly scalable, and capable of generating high-purity EngTregs. Its proprietary immune-evasive engineering is designed to shield allogeneic engineered Tregs from immune rejection and to enable cost-of-goods comparable with biologics. GentiBio states that its engineered regulatory T-cell platform has a unique ability to potently suppress inflammation and autoimmune dysfunction in a tissue-restricted manner while healing damaged tissues, with the potential to reset a dysfunctional immune system and establish lasting immune homeostasis. GentiBio's pipeline includes GNTI 122, which is being evaluated in recent-onset Type 1 diabetes. In June 2026, the company announced it would present clinical data on GNTI 122 at the 2026 Endocrine Society (ENDO) Annual Meeting. In August 2026, GentiBio announced a publication in EMBO Molecular Medicine describing a technology for enabling durable persistence of allogeneic cell therapies. The company is privately held and backed by investors including OrbiMed and the Novartis Venture Fund, whose representatives serve on its board. Its leadership team includes Chief Medical Officer Mark Bach, MD, PhD, and co-founder and Senior Vice President of Research and Development Operations Chandra Patel, PhD. GentiBio emphasizes an experienced team with deep expertise in cell therapy, immunology, and therapeutic development, supported by experienced CMC and clinical teams.

• GentiBio to present clinical data on GNTI 122 in recent-onset Type 1 diabetes at the 2026 Endocrine Society (ENDO) Annual Meeting.

• GentiBio announces publication in EMBO Molecular Medicine describing a technology for enabling durable persistence of allogeneic cell therapies.

Clinical-stage developer of engineered Treg therapies aiming to reset the immune system and replace systemic immunosuppressive therapies.

• GNTI 122

  Clinical-stage engineered Treg candidate being evaluated in recent-onset Type 1 diabetes.

• Engineered Treg (EngTreg) platform

  Modular engineering platform creating optimized Tregs for autoimmune and inflammatory diseases, with autologous and allogeneic approaches.

1. 1Home - GentiBiogentibio.com
2. 2Our Team - GentiBiogentibio.com
3. 3Company Overview - GentiBiogentibio.com
4. 4GentiBio (United States) - Wikidatawikidata.org